Skip to main content
. Author manuscript; available in PMC: 2022 Jan 31.
Published in final edited form as: Leuk Res. 2019 Sep 28;87:106230. doi: 10.1016/j.leukres.2019.106230

Figure 3: Cumulative incidence of relapse by CMV reactivation status based on donor KIR genotype.

Figure 3:

(a) Significant association between CMV reactivation and CIR in patients receiving HCT from KIR Bx donors versus (b) No significant outcomes when the donor is KIR A/A positive. (c) Protective effect of CMV reactivation when donor is 2DS1 positive and (d) Non-significant association between CIR and CMV reactivation when donor is 2DS1 negative.